For Research Purposes Only
Peptides

GLP-3 RT

2381090-40-8GIPGLP-1

$50.00

A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously, studied for its role in metabolic regulation and body composition in clinical research settings.

Dosage
Quantity
1

BUNDLE & SAVE

CoA
Sign Up & Save
We accept
Apple PayVisaDiscoverAmerican ExpressCash AppZelle
Free shipping
Free shipment protection
1-2 day shipping available
Free shipping on all orders
Damage protection Included on all orders
Secure checkout 256-bit SSL

GLP-3 RT is researched for simultaneous activation of three receptor pathways: GIP receptor activity enhances insulin sensitivity, GLP-1 receptor modulates appetite and glucose utilization, and glucagon receptor increases energy expenditure and hepatic glucose output.

This triple-agonist mechanism represents one of the most comprehensive approaches to metabolic research currently studied in preclinical settings.

Weight 0.02 lbs
Purity

>99% HPLC Verified

Dosage

10MG, 20MG, 30MG

CAS

2381090-40-8

Formula

C264H387N65O78

Designation

RUO

Reviews

There are no reviews yet.

Be the first to review “GLP-3 RT”

Your email address will not be published. Required fields are marked *

Compound Information

Technical specifications

MOLECULAR PROFILE

What Is GLP-3 RT?

CAS Number2381090-40-8
Molecular FormulaC264H387N65O78
Purity>99% HPLC Verified
FormLyophilized powder
Research GradeThird-party verified
STORAGE REQUIREMENTS

Stability Information

Avoid freeze/thaw cycles Protect from light Keep refrigerated
Lyophilized (powder)−20°C · 24+ months
Reconstituted2–8°C · ~30 days

Sources & References

Peer-reviewed research

NEW ENGLAND JOURNAL OF MEDICINE

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023 · DOI: 10.1056/NEJMoa2301972 Jastreboff AM, et al.
View Source ↗
THE LANCET

GLP-3 (RT), a GIP/GLP-1/Glucagon Agonist, for People with Type 2 Diabetes — A Phase 2 Trial

2023 Rosenstock J, et al.
View Source ↗
NATURE MEDICINE

GLP-3 (RT) for Metabolic Dysfunction-Associated Steatotic Liver Disease — A Phase 2a Trial

2024 Sanyal AJ, et al.
View Source ↗
SYSTEMATIC REVIEW & META-ANALYSIS

Effects of Once-Weekly GLP-3 (RT) on Weight and Metabolic Markers — A Meta-Analysis of RCTs

2024 Pooled analysis
View Source ↗
PUBMED CENTRAL

Incretin Triple Agonist GLP-3 (RT) in Obesity-Associated Disease Progression

2025
View Source ↗
PUBCHEM DATABASE

GLP-3 (RT) Compound Information — Structure & Properties

View Source ↗
CLINICALTRIALS.GOV

GLP-3 (RT) in Obesity or Overweight (Phase 2 Registry)

View Source ↗
CLINICALTRIALS.GOV

GLP-3 (RT) in Participants with Obesity and Cardiovascular Disease

View Source ↗
CLINICALTRIALS.GOV

GLP-3 (RT) in Type 2 Diabetes with Obesity or Overweight

View Source ↗

Frequently Researched Together

MOTS-C
MOTS-C
$45.00

Peptides

SEMAX
SEMAX
$40.00

Peptides

MT-1
MT-1
$32.00

Peptides

SELANK
SELANK
$40.00

Peptides

GHK-Cu
GHK-Cu
$35.00

Peptides

GLOW
GLOW
$64.00

Blends

KLOW
KLOW
$76.00

Blends

Bacteriostatic Water

Accessories